Provided by Tiger Trade Technology Pte. Ltd.

Nuvectis Pharma, Inc.

7.58
-0.1100-1.43%
Post-market: 7.580.00000.00%16:40 EST
Volume:50.66K
Turnover:383.01K
Market Cap:194.16M
PE:-5.58
High:7.67
Open:7.67
Low:7.45
Close:7.69
52wk High:11.52
52wk Low:4.44
Shares:25.61M
Float Shares:14.54M
Volume Ratio:0.59
T/O Rate:0.35%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3595
EPS(LYR):-1.1103
ROE:-145.00%
ROA:-62.40%
PB:8.09
PE(LYR):-6.83

Loading ...

Company Profile

Company Name:
Nuvectis Pharma, Inc.
Exchange:
NASDAQ
Establishment Date:
2020
Employees:
13
Office Location:
1 Bridge Plaza,Suite 275,Fort Lee,New Jersey,United States
Zip Code:
07024
Fax:
- -
Introduction:
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.

Directors

Name
Position
Ron Bentsur
President, Chief Executive Officer and Chairman
James F. Oliviero
Director
Juan Sanchez
Director
Kenneth Hoberman
Director
Matthew Kaplan
Director

Shareholders

Name
Position
Ron Bentsur
President, Chief Executive Officer and Chairman
Enrique Poradosu
Chief Scientific & Business Officer
Michael Carson
Vice President of Finance
Shay Shemesh
Chief Development and Operations Officer